[
  {
    "ts": null,
    "headline": "Why Amgen (AMGN) Could Beat Earnings Estimates Again",
    "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=51b1f1696dabe7f616465e4fc89afbe8a0327ac06bea8aa40883b771fcd4e24a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760371804,
      "headline": "Why Amgen (AMGN) Could Beat Earnings Estimates Again",
      "id": 137068764,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=51b1f1696dabe7f616465e4fc89afbe8a0327ac06bea8aa40883b771fcd4e24a"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that Repatha (evolocumab) significantly reduced the risk of Major Adverse Cardiovascular Events/MACE in high-risk individuals without a prior history of heart attack or […]",
    "url": "https://finnhub.io/api/news?id=cd0ffecb39693864830cb866f4e1c72bcbaed2c2c70a48b7c1ce9fe8ff0f664d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760359426,
      "headline": "Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention",
      "id": 137066428,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that Repatha (evolocumab) significantly reduced the risk of Major Adverse Cardiovascular Events/MACE in high-risk individuals without a prior history of heart attack or […]",
      "url": "https://finnhub.io/api/news?id=cd0ffecb39693864830cb866f4e1c72bcbaed2c2c70a48b7c1ce9fe8ff0f664d"
    }
  },
  {
    "ts": null,
    "headline": "Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)",
    "summary": "Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.",
    "url": "https://finnhub.io/api/news?id=63ea932b636d77d92d2bc597a54383ba748330dc7182c83cd3d6f0233fe11f10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760326362,
      "headline": "Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)",
      "id": 137066429,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.",
      "url": "https://finnhub.io/api/news?id=63ea932b636d77d92d2bc597a54383ba748330dc7182c83cd3d6f0233fe11f10"
    }
  }
]